Merck price target lowered to $130 from $137 at Guggenheim

Guggenheim lowered the firm’s price target on Merck (MRK) to $130 from $137 and keeps a Buy rating on the shares. While noting shares are down about 2.6% since the company reported Q3 earnings last week, with much of the focus remaining on Gardasil sales in the quarter that were well below expectations, the firm adds that it was “encouraged” by Keytruda’s continued strength and Winrevair’s uptake in its first full quarter on the market.